PorMedTec
Genetically engineered porcine organs for xenotransplantation research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Related Content
PorMedTec is a biotechnology company that develops genetically engineered pigs for medical applications, including xenotransplantation and regenerative medicine. The company was established in February 2017 as a spin-off from Meiji University, founded by Professor Hiroshi Nagashima and Genjiro Miwa. It was created to commercialize the research of the Meiji University International Institute for Bio-Resource Research (MUIIBR), a leading group in animal bioengineering.
Professor Hiroshi Nagashima, Co-CEO and Chief Scientist, has an extensive background in the embryology of large domestic animals and xenotransplantation research. Genjiro Miwa, the other Co-CEO, previously co-founded BioSurface Technology, a company that developed cultured skin substitutes. PorMedTec's business centers on the production and sale of humanized and genetically engineered pig organs, such as pancreatic islets and kidneys, for xenotransplantation. The company also offers made-to-order production of genetically engineered pigs for research and technical consulting for biomaterial cryopreservation.
A core component of PorMedTec's operations is its bioengineering platform, which utilizes genetic modifications, somatic cell cloning, and other advanced reproductive technologies. The company has also developed a proprietary low-cost U-iR (Uterectomy Isolated Rearing) system to produce Designated Pathogen-Free (DPF) pigs suitable for medical use. In a significant milestone, PorMedTec, in collaboration with the U.S. biotech firm eGenesis, successfully produced genetically engineered porcine donors in Japan in February 2024, aiming to address the severe organ donor shortage in the country. The initial focus of this collaboration is on kidney transplants. The company has received funding from investors such as Eight Roads Ventures, Global Brain, and IDDM Network.
Keywords: xenotransplantation, regenerative medicine, organ transplantation, genetic engineering, porcine organs, animal bioengineering, pig cloning, cryopreservation, somatic cell cloning, Designated Pathogen-Free pigs, humanized organs, bioengineering, cell cloning technology, biotechnology, medical-grade pigs